Xue Chen Li
Director/Board Member bei YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.
Vermögen: 5 561 $ am 31.03.2024
Profil
Xue Chen Li is an Independent Non-Executive Director at YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
and a Director at HEC Pharm Co., Ltd.
He holds a doctorate degree from Harvard University, a graduate degree from the University of Alberta, and an undergraduate degree from Nankai University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 4 000 ( 0,00% ) | 5 561 $ | 31.03.2024 |
Aktive Positionen von Xue Chen Li
| Unternehmen | Position | Beginn |
|---|---|---|
| YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Director/Board Member | 25.09.2020 |
HEC Pharm Co., Ltd.
 HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Director/Board Member | - |
Ausbildung von Xue Chen Li
| Harvard University | Doctorate Degree |
| University of Alberta | Graduate Degree |
| Nankai University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
HEC Pharm Co., Ltd.
HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Health Technology |
